Appropriateness of Omeprazole Prescribing in Quebec’s Senior Population

Grégoire, Jean‐Pierre; Moisan, Jocelyne; Chabot, Isabelle; Gaudet, Michel

doi:10.1155/2000/702980

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Databases from the Quebec Health Insurance Board are currently being made available to researchers to study safety issues [32], patterns of use [33,34,35], and the effect of health policy changes on the use of drugs and the related outcomes [36]. Although some of the above studies were supported by public funding only [34,36], others [33,35] were the result of a collaborative effort between public thirdparty payers, academics, and pharmaceutical manufacturers, the former giving researchers access to their administrative databases, the latter providing financial support.…”

Section: Case Study 3: Quebec Experience In Database Sharingmentioning

confidence: 99%

“…Although some of the above studies were supported by public funding only [34,36], others [33,35] were the result of a collaborative effort between public thirdparty payers, academics, and pharmaceutical manufacturers, the former giving researchers access to their administrative databases, the latter providing financial support. The potential gains for the public third party payer in the above studies are obvious in terms of increase knowledge about its own population.…”

Section: Case Study 3: Quebec Experience In Database Sharingmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers

2006

Self Cite

View full text Add to dashboard Cite

Research collaborations between academic researchers, regulatory agencies, and pharmaceutical manufacturers have made the drug development process more efficient and have frequently supported the successful documentation of quality, safety, and efficacy of pharmaceuticals (the so-called three hurdles). Over recent years issues of drug cost, access, and utilization have moved to center stage, giving rise to a "fourth hurdle approval" process by third-party payers. This requires new forms of collaborative research among new players. This contribution highlights the need for a "triangular" relationship in the field of outcomes research between scientists in academia, third-party payer institutions, and pharmaceutical manufacturers. We discuss, and illustrate by case studies, how successful models of collaboration from the drug development process might be relevant to research activities related to the fourth hurdle. Case studies which may provide useful models for collaborative outcomes research include the "International Conference on Harmonization" process, the voluntary consultation procedures established by drug regulatory agencies, and the Quebec experience in database sharing.

show abstract

Section: Case Study 3: Quebec Experience In Database Sharingmentioning

confidence: 99%

Section: Case Study 3: Quebec Experience In Database Sharingmentioning

confidence: 99%

Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers

2006

Self Cite

View full text Add to dashboard Cite

show abstract

Appropriateness of gastric antisecretory therapy in hospital practice

et al. 2003

View full text Add to dashboard Cite

show abstract

Acid-Suppressive Therapy and Risk of Infections: Pros and Cons

Fisher

2017

Clin Drug Investig

View full text Add to dashboard Cite

This narrative review summarises the benefits, risks and appropriate use of acid-suppressing drugs (ASDs), proton pump inhibitors and histamine-2 receptor antagonists, advocating a rationale balanced and individualised approach aimed to minimise any serious adverse consequences. It focuses on current controversies on the potential of ASDs to contribute to infections-bacterial, parasitic, fungal, protozoan and viral, particularly in the elderly, comprehensively and critically discusses the growing body of observational literature linking ASD use to a variety of enteric, respiratory, skin and systemic infectious diseases and complications (Clostridium difficile diarrhoea, pneumonia, spontaneous bacterial peritonitis, septicaemia and other). The proposed pathogenic mechanisms of ASD-associated infections (related and unrelated to the inhibition of gastric acid secretion, alterations of the gut microbiome and immunity), and drug-drug interactions are also described. Both probiotics use and correcting vitamin D status may have a significant protective effect decreasing the incidence of ASD-associated infections, especially in the elderly. Despite the limitations of the existing data, the importance of individualised therapy and caution in long-term ASD use considering the balance of benefits and potential harms, factors that may predispose to and actions that may prevent/attenuate adverse effects is evident. A six-step practical algorithm for ASD therapy based on the best available evidence is presented.

show abstract

Appropriateness of Omeprazole Prescribing in Quebec’s Senior Population

Abstract: Although reimbursement for omeprazole prescriptions has not been restricted in Quebec since January 1, 1994, it was prescribed appropriately for elderly patients in the majority of cases studied.

Cited by 5 publications

References 30 publications

Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers

Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers

Appropriateness of gastric antisecretory therapy in hospital practice

Acid-Suppressive Therapy and Risk of Infections: Pros and Cons

Contact Info

Product

Resources

About